Overview

A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness and safety of decitabine (Dacogen) intravenous injection in patients with Myelodysplastic Syndrome.
Details
Lead Sponsor:
Janssen Korea, Ltd., Korea
Treatments:
Decitabine